Integra LifeSciences (IART) Flags Weak Fundamentals, Analysts Recommend Caution

Integra LifeSciences shares have surged 35.3% to $17.91 over the past six months, but underlying weaknesses suggest investors should approach with caution, according to a StockStory research report published June 5, 2026. The medical device maker’s organic revenue grew at an average annual rate of just 2.3% over two years, lagging its sector. Earnings per share declined 2.4% annually over five years despite revenue growth of 3.6%, indicating shrinking profitability on a per-share basis. Integra LifeSciences carries $2.04 billion in debt against only $236.8 million in cash, resulting in a 5× net-debt-to-EBITDA ratio. This leverage raises refinancing risk and could pressure credit ratings if profitability falters. While the stock trades at a seemingly cheap 6.5× forward price-to-earnings multiple, the report warns the shaky fundamentals create substantial downside risk.